Wednesday, 27 December 2017

NOVEL CISPLATIN TREATMENT EFFECTIVE FOR PERITONEAL MESOTHELIOMA

Aggressive debulking of peritoneal mesothelioma combined with continuous hyperthermic peritoneal perfusion (CHPP) using cisplatin is a novel strategy for the treatment of peritoneal mesothelioma, allowing high regional delivery of chemotherapeutics and hyperthermia while minimizing systemic toxicity. Ten patients with peritoneal mesothelioma ranging in age from 15 to 57 underwent tumor debulking followed by CHPP. Medain follow-up time was ten months.

There was no treatment-related mortality. In eight optimally debulked patients there is no evidence of recurrent disease clinically or by computerized tomography or magnetic resonance imaging scans. Seven patients with symptomatic ascites were completely palliated. CHPP with cisplatin is well tolerated with no significant regional toxicity. Because favorable cisplatin pharmocokinetics suggest the potential for enchanced tumoricidal effect during CHPP, tumor debulking and CHPP may represent an effective strategy for the treatment of peritoneal mesothelioma. "Continuous hyperthermic peritoneal perfusion with cisplatin for the treatment of peritoneal mesothelioma", Ma, et al., Cancer Journal from Scientific American, 3(3):174-9, May-June 1997.

Aggressive debulking of peritoneal mesothelioma combined with continuous hyperthermic peritoneal perfusion (CHPP) using cisplatin is a novel strategy for the treatment of peritoneal mesothelioma, allowing high regional delivery of chemotherapeutics and hyperthermia while minimizing systemic toxicity. Ten patients with peritoneal mesothelioma ranging in age from 15 to 57 underwent tumor debulking followed by CHPP. Medain follow-up time was ten months. There was no treatment-related mortality. In eight optimally debulked patients there is no evidence of recurrent disease clinically or by computerized tomography or magnetic resonance imaging scans. Seven patients with symptomatic ascites were completely palliated.

CHPP with cisplatin is well tolerated with no significant regional toxicity. Because favorable cisplatin pharmocokinetics suggest the potential for enchanced tumoricidal effect during CHPP, tumor debulking and CHPP may represent an effective strategy for the treatment of peritoneal mesothelioma. "Continuous hyperthermic peritoneal perfusion with cisplatin for the treatment of peritoneal mesothelioma", Ma, et al., Cancer Journal from Scientific American, 3(3):174-9, May-June 1997.

NOVEL CISPLATIN TREATMENT EFFECTIVE FOR PERITONEAL MESOTHELIOMA Rating: 4.5 Diposkan Oleh: ABD KADIR Rusdi

Categories

canada (3) cancer (53) women (2)

Popular Posts